This is the current release of the guideline.

This guideline updates a previous version: Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998 Jan;27(1):264-72.

Recommendations are followed by quality of evidence ratings (Grades I, II-1, II-2, II-3, III) which are defined at the end of the "Major Recommendations" field.

Evaluation and Diagnosis

1. Abdominal paracentesis should be performed and ascitic fluid should be obtained from inpatients and outpatients with clinically apparent new-onset ascites (Grade II-3).
2. Since bleeding is sufficiently uncommon, the prophylactic use of fresh frozen plasma or platelets before paracentesis is not recommended (Grade III).

Ascitic Fluid Analysis

3. The initial laboratory investigation of ascitic fluid should include an ascitic fluid cell count and differential, ascitic fluid total protein, and serum-ascitic albumin gradient (SAAG) (Grade II-2).
4. If ascitic fluid infection is suspected, ascitic fluid should be cultured at the bedside in blood culture bottles (Grade II-2).
5. Other studies can be ordered based on pretest probability of disease (Refer to Table 2 in the original guideline document for ascitic fluid laboratory data) (Grade III).

Treatment of Ascites

6. Patients with ascites who are thought to have an alcohol component to their liver injury should abstain from alcohol consumption (Grade II-2).
7. First-line treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol per day [2,000 mg per day]) and diuretics (oral spironolactone and furosemide) (Grade I).
8. Fluid restriction is not necessary unless serum sodium is less than 120 to 125 mmol/L (Grade III).
9. An initial therapeutic abdominal paracentesis should be performed in patients with tense ascites. Sodium restriction and oral diuretics should then be initiated (Grade II-3).
10. Diuretic-sensitive patients should preferably be treated with sodium restriction and oral diuretics rather than with serial paracenteses (Grade III).
11. Liver transplantation should be considered in patients with cirrhosis and ascites (Grade II-3)
.

Treatment of Refractory Ascites

12. Serial therapeutic paracenteses may be performed in patients with refractory ascites (Grade III).
13. Post-paracentesis albumin infusion may not be necessary for a single paracentesis of less than 4 to 5 L. For large-volume paracenteses, an albumin infusion of 8 to 10 g per liter of fluid removed can be considered (Grade II-2).
14. Referral for liver transplantation should be expedited in patients with refractory ascites (Grade II-3).
15. Transjugular intrahepatic portasystemic stent-shunt (TIPS) should be considered in appropriately selected patients who meet criteria similar to those of published randomized trials (Grade I).
16. Peritoneovenous shunt should be considered for patients with refractory ascites who are not candidates for paracenteses, transplant, or TIPS (Grade I).

Hepatorenal Syndrome

17. Albumin infusion plus administration of vasoactive drugs such as octreotide and midodrine should be considered in the treatment of type I hepatorenal syndrome (Grade II-1).
18. Patients with cirrhosis, ascites, and type I hepatorenal syndrome should have an expedited referral for liver transplantation (Grade II-3).

Spontaneous Bacterial Peritonitis (SBP)

19. Patients with ascites admitted to the hospital should undergo abdominal paracentesis. Paracentesis should be repeated in patients (whether in the hospital or not) who develop signs or symptoms or laboratory abnormalities suggestive of infection (e.g., abdominal pain or tenderness, fever, encephalopathy, renal failure, acidosis, or peripheral leukocytosis) (Grade III).
20. Patients with ascitic fluid polymorphonuclear leukocyte (PMN) counts greater than or equal to 250 cells/mm³ (0.25 X 10⁹/L) should receive empiric antibiotic therapy (e.g., intravenous cefotaxime 2 g every 8 hours) (Grade I).
21. Patients with ascitic fluid PMN counts less than 250 cells/mm³ (0.25 X 10⁹/L) and signs and symptoms of infection (temperature >100 degrees F or abdominal pain or tenderness) should also receive empiric antibiotic therapy (e.g., intravenous cefotaxime 2 g every 8 hours) while awaiting results of cultures (Grade II-3).
22. When the ascitic fluid of a patient with cirrhosis is found to have a PMN count greater than or equal to 250 cells/mm³ (0.25 X 10⁹/L), it should also be tested for total protein, lactic dehydrogenase (LDH), glucose, and Gram's stain to assist with the distinction of SBP from secondary peritonitis (Grade II-2).
23. Oral ofloxacin (400 mg twice per day.) can be considered a substitute for intravenous cefotaxime in inpatients without vomiting, shock, grade II (or higher) hepatic encephalopathy, or serum creatinine greater than 3 mg/dL (Grade I).
24. Patients with ascitic fluid PMN counts greater than or equal to 250 cells/mm³ (0.25 X 10⁹/L) and clinical suspicion of SBP should receive 1.5 g albumin per kg body weight within 6 hours of detection and 1.0 g/kg on day 3 (Grade I).

Prevention of SBP

25. Short-term (7 days) inpatient twice-daily norfloxacin (or trimethoprim/sulfamethoxazole) should be given to prevent bacterial infections in patients with cirrhosis and gastrointestinal hemorrhage; a quinolone antibiotic can be given intravenously while the patient is actively bleeding (Grade I).
26. Patients who have survived an episode of SBP should receive long-term prophylaxis with daily norfloxacin (or trimethoprim/sulfamethoxazole) because this is the most data-supported indication for long-term outpatient prophylaxis (Grade I).
27. In patients with cirrhosis and ascites but no gastrointestinal bleeding, either short-term (inpatient-only) or long-term outpatient use of daily norfloxacin (or trimethoprim/sulfamethoxazole) can be justified when the ascitic fluid total protein is less than or equal to 1 g/dL or serum bilirubin greater than 2.5 mg/dL (Grade I).

Definitions:

Quality of Evidence

Grade I: Randomized controlled trials

Grade II-1: Controlled trials without randomization

Grade II-2: Cohort or case-control analytic studies

Grade II-3: Multiple time series, dramatic uncontrolled experiments

Grade III: Opinions of respected authorities, descriptive epidemiology

None provided

The type of evidence is specifically stated for each recommendation (see the "Major Recommendations" field).

Not applicable: The guideline was not adapted from another source.

1998 Jan (revised 2004 Mar)

American Association for the Study of Liver Diseases - Private Nonprofit Research Organization

American Association for the Study of Liver Diseases

Practice Guidelines Committee

Primary Author: Bruce A. Runyon, MD, Chief, Liver Service, Loma Linda University Medical Center, Loma Linda CA

Committee Members: K. Rajender Reddy, MD, Chair; Henry C. Bodenheimer, Jr., MD; Bruce R. Bacon, MD; William D. Carey, MD; Robert L. Carithers, MD; James E. Everhart, MD; Thomas W. Faust, MD; D. Roy Ferguson, MD; Norman D. Grace, MD; Elizabeth Hespenheide, RN, BSN; Maureen Jonas, MD; Michael R. Lucey, MD; Timothy M. McCashland, MD; Brian J. McMahon, MD; F. Fred Poordad, MD; Robert Reindollar, MD; Leonard B. Seeff, MD; Margaret C. Shuhart, MD; Brent A. Tetri, MD; Zobair Younossi, MD

Not stated

This is the current release of the guideline.

This guideline updates a previous version: Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998 Jan;27(1):264-72.

None available

This NGC summary was completed by ECRI on May 9, 2003. The information was verified by the guideline developer as of June 12, 2003. The guideline was updated by ECRI on July 27, 2004. The updated information was verified by the guideline developer as of August 25, 2004. This summary was updated by ECRI Institute on July 28, 2008 following the U.S. Food and Drug Administration advisory on fluoroquinolone antimicrobial drugs.

This NGC summary is based on the original guideline, which is subject to the American Association for the Study of Liver Diseases' copyright restrictions.